Immuneering Past Earnings Performance
Past criteria checks 0/6
Immuneering's earnings have been declining at an average annual rate of -31.9%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 104.2% per year.
Key information
-31.9%
Earnings growth rate
16.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -104.2% |
| Return on equity | -68.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Mar 19Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Jan 06
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Aug 17Immuneering wins FDA nod to study lead asset in solid tumors
Sep 30Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
Sep 02Immuneering initiated a Buy by Chardan, PT set to $18
Jul 08Revenue & Expenses BreakdownBeta
How Immuneering makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -54 | 16 | 43 |
| 31 Dec 23 | 0 | -53 | 17 | 42 |
| 30 Sep 23 | 0 | -52 | 16 | 40 |
| 30 Jun 23 | 0 | -52 | 16 | 39 |
| 31 Mar 23 | 0 | -51 | 16 | 37 |
| 31 Dec 22 | 0 | -51 | 16 | 36 |
| 30 Sep 22 | 1 | -48 | 15 | 34 |
| 30 Jun 22 | 1 | -44 | 13 | 31 |
| 31 Mar 22 | 2 | -40 | 11 | 30 |
| 31 Dec 21 | 2 | -34 | 8 | 27 |
| 30 Sep 21 | 3 | -29 | 6 | 23 |
| 30 Jun 21 | 3 | -24 | 4 | 22 |
| 31 Mar 21 | 3 | -20 | 4 | 18 |
| 31 Dec 20 | 2 | -17 | 3 | 15 |
| 31 Dec 19 | 2 | -8 | 3 | 4 |
Quality Earnings: IMRX is currently unprofitable.
Growing Profit Margin: IMRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMRX is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.
Accelerating Growth: Unable to compare IMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.9%).
Return on Equity
High ROE: IMRX has a negative Return on Equity (-68.82%), as it is currently unprofitable.